Current trends in pediatric aggressive B-cell lymphomas treatment
Nowadays due to modern risk-adapted treatment protocols high survival rates have been achieved in patients with aggressive B-cell lymphomas, even at stages III–IV these indicators overrun 90 %. Mainly these successes were associated with the inclusion of rituximab in the standard chemotherapy regime...
Saved in:
| Main Authors: | Yu. S. Korkina, T. T. Valiev |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2021-06-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/471 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Non-Hodgkin’s Lymphomas in Children: 25-Year Clinical Experience
by: TT Valiev, et al.
Published: (2016-10-01) -
Primary Lymphoma of the Gynecologic Tract: A Comprehensive Pathologic Analysis of 15 Cases
by: Haneen Al-Maghrabi, et al.
Published: (2025-04-01) -
Primary diffuse large B-cell lymphoma of the breast: Treatment and long-term outcome of two cases
by: Rajesh Kashyap, et al.
Published: (2020-01-01) -
The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma
by: T. D. Lutskaya, et al.
Published: (2014-07-01) -
Real‐World Data on Lymphoma in Adolescents and Young Adults (AYA)—Report From the Lymphoma and Related Diseases Registry (LaRDR)
by: Evangeline Y. Wong, et al.
Published: (2025-02-01)